Lantern Pharma Inc. develops AI-driven precision oncology therapies and research platforms for cancer drug discovery. The company uses its proprietary RADR® platform to identify and advance small-molecule oncology candidates, including LP-300, LP-184 and LP-284, and develops STAR-001 for CNS cancers through Starlight Therapeutics, its wholly owned subsidiary.
Recurring news includes clinical-program updates for lung cancer, hematologic cancers, sarcomas and brain cancers; FDA and trial-design communications; financial results; and commercialization of AI tools such as withZeta.ai and predictBBB.ai. Company updates also cover subscription-based platform access, computational biology features and enterprise deployment for biomedical research and drug-development users.
Lantern Pharma (NASDAQ: LTRN) management will present at the ThinkEquity Conference in New York on October 15, 2026.
The presentation is scheduled for 3:30 p.m. ET at the Mandarin Oriental. Management will also be available for one-on-one meetings throughout the conference.
Lantern Pharma (NASDAQ: LTRN) received Taiwan approvals to open Part 2 of its Phase 2 HARMONIC trial of LP-300. The Taiwan FDA approved the amended protocol in September 2026; the lead site's ethics board approved it on September 29. That site is open to enrollment and screening patients.
The single-arm study enrolls never-smokers with advanced non-small-cell lung cancer carrying the EGFR exon 21 L858R mutation after progression on EGFR-targeted treatment. LP-300 is combined with carboplatin and pemetrexed for up to eight cycles, increased from six. Preliminary median progression-free survival—time without disease worsening—was 8.9 months among nine L858R patients completing six cycles, versus 8.3 months among all 16 L858R patients. Three of the nine had not progressed; these exploratory findings require confirmation. A U.S. central ethics board also approved the amendment, and academic sites have begun identifying eligible patients.
Lantern Pharma (NASDAQ: LTRN) closed a registered direct offering that raised approximately $4 million in gross proceeds before fees and expenses. The offering comprised 3,669,725 shares of common stock, or pre-funded warrants in their place, at $1.09 each.
In a concurrent private placement, Lantern issued unregistered warrants to purchase up to 3,669,725 additional shares at an exercise price of $1.09 per share. Full exercise for cash would provide approximately $4 million in additional gross proceeds. Exercise is subject to stockholder approval of the issuance of the underlying shares and begins on that approval’s effective date; the warrants expire five years following approval. Rodman & Renshaw acted as exclusive placement agent. Lantern intends to use net proceeds for working capital and other general corporate purposes.
Lantern Pharma (LTRN) entered a definitive agreement for a registered direct offering expected to generate approximately $4 million in gross proceeds. The agreement covers 3,669,725 common shares, or pre-funded warrants in their place, at $1.09 each. In a concurrent private placement, Lantern will issue unregistered warrants to purchase up to 3,669,725 common shares at an exercise price of $1.09 per share.
Those warrants become exercisable on the effective date of stockholder approval for the underlying share issuance and expire five years after that approval. Full exercise for cash could provide approximately $4 million in additional gross proceeds. The offering is expected to close on or about September 30, 2026, subject to customary closing conditions. Placement-agent fees and other offering expenses will reduce the initial proceeds; Lantern intends to use the net proceeds for working capital and other general corporate purposes.
Lantern Pharma (LTRN) will present the growth plan for its Open-Medicine AI (OMAI) multi-agentic drug development platform in a live webinar today, September 23, 2026, at 12:30 PM Eastern.
OMAI is a wholly owned subsidiary whose core capabilities were developed within Lantern’s clinical oncology programs, initially launched as withZeta.ai in April 2026 and focused on rare cancers, and is now expanding into additional diseases, therapy types, and development stages.
The 45‑minute session, led by CEO Panna Sharma with senior scientific and platform leaders, will cover market opportunity, customer usage and feedback, live demos of differentiated capabilities, product roadmap, platform economics, performance benchmarks, partnership discussions, and OMAI’s contribution to Lantern’s pipeline and long‑term shareholder value.
Lantern Pharma (LTRN) received a USPTO Notice of Allowance for a U.S. patent on LP‑284 treatment methods for mantle cell lymphoma (MCL), double‑hit lymphoma (DHL), and other blood cancers, with expected protection into 2042 once issued.
The allowed claims cover LP‑284 as a monotherapy and in combination with specified anti‑cancer agents, and include intravenous and intraperitoneal administration routes. This method‑of‑treatment patent will layer on top of existing LP‑284 composition‑of‑matter patents that protect the drug into 2039 across major markets including the United States, European Union, Japan, China, India, Mexico, Korea, and Australia. LP‑284 holds three FDA Orphan Drug Designations and is in an ongoing Phase 1a trial (NCT06132503) in relapsed or refractory B‑cell non‑Hodgkin's lymphomas and solid tumors, supported by preclinical potency data and an estimated $4 billion annual global blood cancer market opportunity.
Lantern Pharma (LTRN) will host a live webinar on September 23, 2026 at 12:30 PM Eastern to present the business model, development roadmap, and value proposition of its Open-Medicine AI subsidiary and platform.
The session will detail how Open-Medicine AI’s multi-agentic AI co-scientists, first commercialized in withZeta.ai for rare and aggressive cancers, are being extended to additional disease categories, new therapeutic modalities, and downstream development challenges such as trial design, patient selection, and regulatory strategy. The 45-minute event, led by Lantern president and CEO and Open-Medicine AI founder and CEO Panna Sharma, will include a 30–35 minute presentation followed by live Q&A.
Lantern Pharma (NASDAQ: LTRN) reported second quarter 2026 results and portfolio progress, including the establishment of Open Medicine AI (OMAI) as a separate, wholly owned company with board-approved commercial licensing agreements for its multi-agent AI co-scientist platform, which already has paying subscription tiers and two engineering centers.
Emerging Phase 2 HARMONIC™ data for LP-300 in EGFR exon 21 L858R NSCLC showed median progression-free survival of 8.9 months in patients completing six cycles (n=9) versus 8.4 months across the L858R cohort (n=16), with a hazard ratio of 0.37 and a 77% clinical benefit rate. The FDA raised no objections to protocol amendments that focus enrollment on L858R patients, extend LP-300 to eight cycles, and move to a single-arm design.
For LP-184 (zirdafulven), the EMA cleared an investigator-initiated Phase 1b/2 bladder cancer trial using a dual biomarker strategy, and the USPTO issued a Notice of Allowance for a three-gene expression signature patent. Lantern ended the quarter with $7.4 million in cash, cash equivalents, and marketable securities, boosted by $4.4 million in gross proceeds from a May 2026 registered direct offering. Loss from operations declined about 25% year over year to approximately $3.5 million in Q2 2026.
Lantern Pharma (NASDAQ: LTRN), an AI-focused oncology company using its RADR® and Open-Medicine platforms, will host a webcast to review its second quarter 2026 operating and financial results on Friday, August 14, 2026 at 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time.
According to Lantern Pharma, management will discuss results for the quarter ended June 30, 2026 and provide guidance on upcoming milestones, clinical trials, and developments related to its AI platforms. The webcast will be led by President and CEO Panna Sharma, alongside other management team members, and a replay will be available on the company’s investor relations website.
Lantern Pharma (Nasdaq: LTRN) has created a separate company, Open-Medicine AI (OMAI), to commercialize and expand its multi-agentic AI co-scientist platform previously launched as withZeta.ai. Lantern has executed commercial licensing agreements granting OMAI access to withZeta.ai-related models, data, algorithms, and other assets and personnel, following Board approval and aligning with the framework of Lantern’s May 2026 registered direct financing.
OMAI will advance the multi-agent system first proven in oncology and rare cancers and extend it into additional disease areas, supported by AI Centers of Excellence in Dallas, Texas and Bengaluru, India. The platform integrates specialized AI agents, rare-cancer knowledge bases, ZetaOmics™ multi-omic analytics, and generative chemistry tools to support real-world drug discovery and development in a global AI market projected to exceed $10 billion by 2030.